Concurrent targeting of MAP3K3 and BRD4 by miR-3140-3p overcomes acquired resistance to BET inhibitors in neuroblastoma cells

Neuroblastoma (NB) harboring MYCN amplification is a refractory disease with a poor prognosis. As BRD4, an epigenetic reader belonging to the bromodomain and extra terminal domain (BET) family, drives transcription of MYCN in NB cells, BET inhibitors (BETis) are considered useful for NB therapy. How...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Chang, Gen, Yasuyuki, Tanimoto, Kousuke, Muramatsu, Tomoki, Inoue, Jun, Inazawa, Johji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253920/
https://www.ncbi.nlm.nih.gov/pubmed/34258104
http://dx.doi.org/10.1016/j.omtn.2021.05.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253920/
https://www.ncbi.nlm.nih.gov/pubmed/34258104
http://dx.doi.org/10.1016/j.omtn.2021.05.001

Ejemplares similares